You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
McKesson
Boehringer Ingelheim
Moodys
Harvard Business School

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,364,493

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,364,493
Title:Methods and compositions for enhancing the uptake of therapeutic agents by target cells
Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Inventor(s): Luo; Yongzhang (Beijing, CN), Chen; Yang (Beijing, CN), Fu; Yan (Beijing, CN), Jia; Lin (Beijing, CN), Chang; Guodong (Beijing, CN)
Assignee: Tsinghua University (Beijing, CN) Beijing Protgen LTD. (Beijing, CN)
Application Number:14/008,428
Patent Claims:see list of patent claims

Details for Patent 9,364,493

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Tsinghua University (Beijing, CN) Beijing Protgen LTD. (Beijing, CN) 2031-03-28 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Merck
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.